Recipharm AB publishes report for the fourth quarter and full year 2020
October – December 2020 · Net sales amounted to SEK 2,812 million (1,981), an increase of 42% · EBITA increased by 65% and amounted to SEK 378 million (230) corresponding to an EBITA margin of 13.5% (11.6) · Operating profit (EBIT) amounted to SEK 339 million (117) and was affected by non-recurring items of SEK +54 million (-52) · Profit after tax amounted to SEK 223 million (90) corresponding to a net margin of 7.9% (4.5) · Earnings per share amounted to SEK 2.20 (1.32) before dilution and SEK 2.19 (1.32) after dilution. Core EPS amounted to SEK 1.40 (2.55) · Leverage